HC Wainwright Has Pessimistic View of Evolus FY2026 Earnings

Evolus, Inc. (NASDAQ:EOLS) – Equities research analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for Evolus in a note issued to investors on Monday, March 30th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.22) for the year, down from their previous forecast of ($0.17). HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Evolus’ FY2027 earnings at $0.19 EPS, FY2028 earnings at $0.64 EPS, FY2029 earnings at $1.04 EPS and FY2030 earnings at $1.41 EPS.

Evolus (NASDAQ:EOLS) last issued its earnings results on Tuesday, March 3rd. The company reported $0.00 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The business had revenue of $90.30 million during the quarter, compared to analyst estimates of $89.58 million.

A number of other research analysts also recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd. Wall Street Zen downgraded shares of Evolus from a “buy” rating to a “hold” rating in a research note on Sunday, March 15th. Mizuho set a $15.00 price objective on shares of Evolus in a report on Wednesday, February 4th. Needham & Company LLC reissued a “hold” rating on shares of Evolus in a research report on Wednesday, December 24th. Finally, Stifel Nicolaus reduced their target price on Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, January 13th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Evolus currently has an average rating of “Moderate Buy” and an average target price of $16.00.

Evolus Stock Up 4.3%

Shares of EOLS stock opened at $4.11 on Wednesday. The firm has a 50 day moving average of $4.65 and a 200-day moving average of $5.88. The company has a market cap of $267.40 million, a price-to-earnings ratio of -5.07 and a beta of 1.02. Evolus has a 52 week low of $3.86 and a 52 week high of $12.51.

Insider Buying and Selling

In related news, insider Rui Avelar sold 29,996 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total value of $146,680.44. Following the completion of the sale, the insider directly owned 430,542 shares of the company’s stock, valued at approximately $2,105,350.38. This represents a 6.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider David Moatazedi sold 116,720 shares of the firm’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total value of $570,760.80. Following the transaction, the insider owned 618,369 shares in the company, valued at approximately $3,023,824.41. This trade represents a 15.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 163,504 shares of company stock worth $797,184 in the last 90 days. Corporate insiders own 6.10% of the company’s stock.

Institutional Trading of Evolus

Several institutional investors and hedge funds have recently made changes to their positions in the company. State of Alaska Department of Revenue bought a new position in shares of Evolus during the third quarter valued at about $26,000. Larson Financial Group LLC grew its position in Evolus by 136.6% in the 4th quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after purchasing an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in Evolus in the 4th quarter valued at about $34,000. Wexford Capital LP purchased a new stake in Evolus in the 3rd quarter valued at about $37,000. Finally, Aquatic Capital Management LLC bought a new position in shares of Evolus during the 3rd quarter worth approximately $48,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.